Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10951849 | 0.81 | LMNA (0.34) | LMNASMN1; SMN2CA2 | |
| SCHEMBL11426170 | 0.77 | PDE10A (0.47) | LMNAGLP1RTLR7SMN1; SMN2 | |
| SCHEMBL24096383 | 0.76 | LMNA (0.40) | LMNARAB9ATLR7SMN1; SMN2CA1 | |
| SCHEMBL29698777 | 0.76 | LMNA (0.40) | LMNARAB9ATLR7SMN1; SMN2CA1 | |
| SCHEMBL4806359 | 0.76 | SMN1; SMN2 (0.39) | LMNAGLP1RTLR7SMN1; SMN2 | |
| SCHEMBL6364307 | 0.76 | LMNA (0.50) | LMNARAB9ASMN1; SMN2 | |
| SCHEMBL18893674 | 0.76 | GLP1R (0.36) | LMNAGLP1RRAB9ATLR7SMN1; SMN2 | |
| SCHEMBL22024694 | 0.74 | LMNA (0.41) | LMNARAB9A | |
| SCHEMBL29950870 | 0.74 | LMNA (0.41) | LMNARAB9A | |
| SCHEMBL27826697 | 0.71 | GLP1R (0.42) | GLP1RCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114748622-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-114732910-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-111601593-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2020-08-28 | — | — | CN | disclosed |